X4 Pharmaceuticals Inc (NASDAQ: XFOR) is a biopharmaceutical company that develops and commercializes drug candidates targeting rare diseases and other conditions. The company generates revenue through product sales and licensing arrangements, including a License and Supply Agreement with Norgine Pharma UK Limited executed January 13, 2025. X4 operates as a single reporting segment, per its 10-K filed March 17, 2026. The company relies on third-party contract manufacturers, including Catalent Inc. under a Master Services Agreement dating to 2015, for drug supply. It also holds a license agreement with Genzyme Corporation, a Sanofi company, originating from 2014. Leadership as of March 17, 2026 includes Adam R. Craig, M.D., Ph.D., M.B.A. as President, Chief Executive Officer, and Executive Chairman, and David Kirske as Chief Financial Officer. PricewaterhouseCoopers LLP, based in Boston, Massachusetts, has served as the company's auditor since 2016. The balance sheet as of December 31, 2025 reflects long-term debt, a warrant liability, deferred revenue, goodwill, and an intangible asset.

Revenue model

Product sales revenue and licensing arrangements, including a License and Supply Agreement with Norgine Pharma UK Limited (executed January 13, 2025). Deferred revenue appears on both current and long-term portions of the balance sheet as of December 31, 2025, per the 10-K filed March 17, 2026.

Products and services

Drug candidates targeting rare diseases. Specific approved product and pipeline candidates are referenced in the filing but not named in the available excerpts. The company holds a license from Genzyme Corporation (a Sanofi company) and has a License and Supply Agreement with Norgine Pharma UK Limited as of January 13, 2025.

Customers and end markets

Hospitals, physicians, patients, and healthcare payors are identified as the key adoption stakeholders for approved products, per the 10-K filed March 17, 2026. Market acceptance depends on hospital and insurance formulary placement.

Value-chain role

Drug developer and commercializer. Manufacturing is outsourced to contract manufacturers including Catalent Inc. and Aptuit (Oxford) Limited. The company retains sales and marketing responsibilities for its approved product and may selectively partner with third parties for commercialization.

Geographic exposure

United States primary market, with regulatory activity and potential commercialization in foreign jurisdictions referenced in the 10-K filed March 17, 2026. A licensing agreement with Norgine Pharma UK Limited (January 13, 2025) indicates activity outside the United States.

Source: SEC 10-K, filed 2026-03-17

Industry: Biological Products, (No Diagnostic Substances) Peers: Atreca, Inc. ZEO ScientifiX Inc Curis Inc Senti Biosciences Inc Korro Bio Inc ImmuCell Corp Pyxis Oncology Inc SQZ Biotechnologies Co Surface Oncology, Inc.